PBM

Propel Bio Management Portfolio holdings

AUM $191M Turnover 36.59%
1-Year Est. Return 102.42%
This Fund
S&P 500
This Quarter Est. Return
-8.08%
1 Year Est. Return
+102.42%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$154M
AUM Growth
-$17.6M
Cap. Flow
-$217K
Cap. Flow %
-0.14%
Top 10 Hldgs %
83.26%
Holding
32
New
4
Increased
4
Reduced
–
Closed
8
Avg Time Held
0.4 years
Top 10 Avg Time Held
0.3 years
Top 20 Avg Time Held
0.3 years

Top Buys

Rank Stock Value
1
PAGP icon
Plains GP Holdings
PAGP
+$25.2M
2
ABEO icon
Abeona Therapeutics
ABEO
+$6.37M
3
VRCA icon
Verrica Pharmaceuticals
VRCA
+$3.26M
4
ARDX icon
Ardelyx
ARDX
+$2.32M
5
APLT icon
Applied Therapeutics
APLT
+$2.16M

Top Sells

Rank Stock Value
1
HIGH icon
Simplify Enhanced Income ETF
HIGH
+$28M
2
DAWN icon
Day One Biopharmaceuticals
DAWN
+$4.47M
3
MBB icon
iShares MBS ETF
MBB
+$2.07M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$1.76M
5
MRNS icon
Marinus Pharmaceuticals, Inc
MRNS
+$1.63M

Sector Composition

Rank Sector Weight
1 Healthcare 79.89%
2 Energy 16.75%
3 Technology 2.16%
4 Miscellaneous 1.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
APLT icon
1
DELISTED
Applied Therapeutics
APLT
$30.7M 19.89%
6,567,858
+455,952
+7% +$2.16M
2023 Q4
2 quarters
PAGP icon
2
Plains GP Holdings
PAGP
$5.37B
$25.8M 16.75%
+1,372,360
New +$25.2M
2024 Q2
0 quarters
TCRX icon
3
TScan Therapeutics
TCRX
$14.3M
$12.2M 7.92%
2,087,139
– –
2023 Q4
2 quarters
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$10.6B
$12.1M 7.82%
43,032
– –
2023 Q4
2 quarters
ACHV icon
5
Achieve Life Sciences
ACHV
$722M
$11.5M 7.48%
2,453,092
– –
2024 Q1
1 quarter
PHAT icon
6
Phathom Pharmaceuticals
PHAT
$599M
$8.96M 5.81%
869,927
– –
2023 Q4
2 quarters
AKRO icon
7
DELISTED
Akero Therapeutics
AKRO
$7.69M 4.99%
327,752
– –
2023 Q4
2 quarters
RNAM
8
DELISTED
Avidity Biosciences
RNAM
$7.29M 4.73%
178,500
– –
2023 Q4
2 quarters
ARDX icon
9
Ardelyx
ARDX
$824M
$6.85M 4.44%
924,583
+330,409
+56% +$2.32M
2023 Q4
2 quarters
ABEO icon
10
Abeona Therapeutics
ABEO
$249M
$5.29M 3.43%
+1,248,044
New +$6.37M
2024 Q2
0 quarters
FULC icon
11
Fulcrum Therapeutics
FULC
$280M
$4.65M 3.02%
750,000
– –
2023 Q4
2 quarters
LONA icon
12
LeonaBio Inc
LONA
$50.8M
$3.96M 2.57%
149,279
– –
2023 Q4
2 quarters
TSAT icon
13
Telesat
TSAT
$673M
$3.33M 2.16%
365,781
+75,000
+26% +$610K
2023 Q4
2 quarters
VRCA icon
14
Verrica Pharmaceuticals
VRCA
$65.8M
$3.1M 2.01%
+42,494
New +$3.26M
2024 Q2
0 quarters
KURA icon
15
Kura Oncology
KURA
$855M
$2.68M 1.74%
130,000
– –
2023 Q4
2 quarters
EIGR
16
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.85M 1.2%
146,381
– –
2023 Q4
2 quarters
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$1.21B
$1.71M 1.11%
83,259
– –
2024 Q1
1 quarter
KYMR icon
18
Kymera Therapeutics
KYMR
$8.88B
$1.68M 1.09%
56,359
– –
2023 Q4
2 quarters
KYN icon
19
Kayne Anderson Energy Infrastructure Fund
KYN
$2.4B
$1.52M 0.99%
147,033
– –
2023 Q4
2 quarters
TRVI icon
20
Trevi Therapeutics
TRVI
$1.72B
$775K 0.5%
260,000
– –
2024 Q1
1 quarter
HELP
21
Helus Pharma Inc. Common Stock
HELP
$758M
$230K 0.15%
22,368
– –
2023 Q4
2 quarters
DAWN icon
22
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-270,664
Closed -$4.47M –
HIGH icon
23
Simplify Enhanced Income ETF
HIGH
$58M
– –
-1,492,581
Closed -$28M –
LQD icon
24
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
$29.2B
– –
-4,456
Closed -$485K –
MBB icon
25
iShares MBS ETF
MBB
$35.7B
– –
-22,400
Closed -$2.07M –
1
2

Similar funds

CFG
Capital Financial Group Greenwood Village, Colorado $191M AUM
MWM
Magnolia Wealth Management Dothan, Alabama $191M AUM 17.58% 1-Year Est. Return
ALWM
Andrews Lucia Wealth Management Danville, California $191M AUM 24.94% 1-Year Est. Return
PFA
Pillar Financial Advisors Louisville, Kentucky $191M AUM 21.21% 1-Year Est. Return
NWM
Navigoe Wealth Management Redondo Beach, California $191M AUM 25.21% 1-Year Est. Return
MCA
Martin Capital Advisors San Antonio, Texas $191M AUM 42.42% 1-Year Est. Return
EMCIP
Ewing Morris & Co Investment Partners Toronto, Ontario, Canada $191M AUM 23.88% 1-Year Est. Return
HPM
H. Partners Management New York $191M AUM 5.95% 1-Year Est. Return

Propel Bio Management's Q2 2024 Portfolio in Review

As of Q2 2024, Propel Bio Management held 32 positions worth $154M, down 10% from $172M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Propel Bio Management's Q2 2024 filing shows 4 new, 4 increased and 8 closed positions. Its largest new stake was Plains GP Holdings: 1,372,360 shares worth $25.8M. The largest sale was Simplify Enhanced Income ETF, an estimated $28M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 80% a quarter earlier, followed by Energy and Technology.

  • Propel Bio Management's largest Q2 2024 buy was Plains GP Holdings: 1,372,360 shares worth $25.8M.
  • Propel Bio Management added most to Ardelyx in Q2 2024, an estimated $2.32M increase.
  • Propel Bio Management fully exited Simplify Enhanced Income ETF in Q2 2024, selling an estimated $28M.
  • Propel Bio Management's ten largest holdings make up 83% of its $154M portfolio in Q2 2024.
  • Propel Bio Management opened 4 new positions and closed 8 in Q2 2024.
  • Propel Bio Management's portfolio value fell 10% quarter-over-quarter to $154M.

Based on Propel Bio Management's 13F filing for Q2 2024, filed 12 Aug 2024.